HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holdsworth, C. H. Articles by Van den Abbeele, A. D. Search for Related Content PubMed PubMed Citation Articles by Holdsworth, C. H. Articles by Van den Abbeele, A. D. Social Bookmarking                      What's this? Hotlight (NEW!) What's Hotlight?

CT and PET: Early Prognostic Indicators of Response to Imatinib Mesylate in Patients with Gastrointestinal Stromal Tumor

¹ Massachusetts College of Pharmacy and Health Sciences, 4 Brook Rd., Unit 11, Salem, NH 03079.
² Dana-Farber Cancer Institute, Boston, MA.
³ University of California Davis School of Medicine, Sacramento, CA.
⁴ Brigham and Women's Hospital, Boston, MA.

OBJECTIVE. We report results from a pilot study aimed at optimizing the use of CT bidimensional measurements and ¹⁸F-FDG PET maximum standardized uptake values (SUVs-_max) for determining response to prolonged imatinib mesylate treatment in patients with advanced gastrointestinal stromal tumors (GISTs).

SUBJECTS AND METHODS. Sixty-three patients enrolled in a multicenter trial evaluating imatinib mesylate therapy for advanced GIST underwent FDG PET at baseline and 1 month after initiation of treatment. Of these 63 patients, 58 underwent concomitant CT. Time-to-treatment failure (TTF) was used as the outcome measure. Patients were followed up over a range of 23.7 to 37 months (median, 31.7 months). The predictive power of change in CT bidimensional measurements, change in PET SUV_max, and PET SUV_max at 1 month after initiation of treatment were determined, optimized, and compared. The effectiveness of combining metrics was also evaluated.

RESULTS. Both a threshold PET SUV_max value of 2.5 at 1 month (p = 0.04) and the European Organization for Research and Treatment of Cancer (EORTC) criteria for partial response on FDG PET (25% reduction in PET SUV_max) at 1 month (p = 0.004) were predictive of prolonged treatment success. The Southwest Oncology Group (SWOG) criteria for partial response (³ 50% reduction in CT bidimensional measurements) at 1 month were not predictive (p = 0.55) of TTF. Optimizing metrics improved results performance. An optimized PET SUV_max threshold of 3.4 (p = 0.00002), a reduction in the SUV_max of 40% (p = 0.002), and an optimized CT bidimensional measurement threshold—that is, no growth from baseline to 1 month (p = 0.00005)—outperformed the existing standards (i.e., EORTC and SWOG criteria). Combinations of metrics did not improve performance.

CONCLUSION. The two best metrics were the optimized PET SUV_max threshold of 3.4 at 1 month (p = 0.00002) and the optimized CT bidimensional measurement threshold (no growth from baseline to 1 month, p = 0.00005) in this patient group.

Keywords: CT • gastrointestinal stromal tumor • imatinib mesylate • oncologic imaging • PET

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. B. Contractor and E. O. Aboagye Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET J. Nucl. Med., May 1, 2009; 50(Suppl_1): 97S - 105S. [Abstract] [Full Text] [PDF]

				S. Stacchiotti, P. Collini, A. Messina, C. Morosi, M. Barisella, R. Bertulli, C. Piovesan, P. Dileo, V. Torri, A. Gronchi, et al. High-Grade Soft-Tissue Sarcomas: Tumor Response Assessment--Pilot Study to Assess the Correlation between Radiologic and Pathologic Response by Using RECIST and Choi Criteria Radiology, May 1, 2009; 251(2): 447 - 456. [Abstract] [Full Text] [PDF]

				L. K. Shankar, A. Van den Abbeele, J. Yap, R. Benjamin, S. Scheutze, and T.J. FitzGerald Considerations for the Use of Imaging Tools for Phase II Treatment Trials in Oncology Clin. Cancer Res., March 15, 2009; 15(6): 1891 - 1897. [Abstract] [Full Text] [PDF]

				A. A. Adjei, M. Christian, and P. Ivy Novel Designs and End Points for Phase II Clinical Trials Clin. Cancer Res., March 15, 2009; 15(6): 1866 - 1872. [Abstract] [Full Text] [PDF]

				J. O. Prior, M. Montemurro, M.-V. Orcurto, O. Michielin, F. Luthi, J. Benhattar, L. Guillou, V. Elsig, R. Stupp, A. B. Delaloye, et al. Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor J. Clin. Oncol., January 20, 2009; 27(3): 439 - 445. [Abstract] [Full Text] [PDF]

				J. L. Spratlin, N. J. Serkova, and S. G. Eckhardt Clinical Applications of Metabolomics in Oncology: A Review Clin. Cancer Res., January 15, 2009; 15(2): 431 - 440. [Abstract] [Full Text] [PDF]